Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

First Posted Date
2008-08-26
Last Posted Date
2020-11-23
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
18
Registration Number
NCT00741455
Locations
πŸ‡ΊπŸ‡Έ

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

First Posted Date
2008-08-25
Last Posted Date
2010-01-28
Lead Sponsor
Institut Paoli-Calmettes
Target Recruit Count
50
Registration Number
NCT00740467
Locations
πŸ‡«πŸ‡·

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

First Posted Date
2008-07-11
Last Posted Date
2023-05-03
Lead Sponsor
Ohio State University
Target Recruit Count
26
Registration Number
NCT00713193
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University, Columbus, Ohio, United States

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

First Posted Date
2008-06-25
Last Posted Date
2008-06-25
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
9
Registration Number
NCT00705120
Locations
πŸ‡ΊπŸ‡Έ

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-04-15
Last Posted Date
2018-02-23
Lead Sponsor
Pfizer
Target Recruit Count
178
Registration Number
NCT00658359
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

UCLA Medical Center, Los Angeles, California, United States

and more 61 locations
Β© Copyright 2024. All Rights Reserved by MedPath